What is ADRX's market cap?

$1.59B, based on the Nov 12 close of $14.91.

How much of ADRX is sold short?

1.8M shares, 3.4% of float, as of Oct 30, 2026.

What sector is ADRX in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ADRXHealthcarePharmaceuticals

ADARx Pharmaceuticals, Inc. Common Stock (ADRX)

$14.91+12.11%

Close Nov 12, 2026 · split-adjusted

Nov 12, 2026$14.91▼ 22.95% in range

Sep 25, 2026Low $13.23 · High $20.64Nov 12, 2026

What changed · written from our data

As of Nov 12, 2026

ADARx Pharmaceuticals closed at $14.91 on Nov 12, up 12.11%, 27.7% below its highest close since Sep 25. Volume of 994.9K shares was 2.56× its 20-day average (well above normal).

Split-adjusted performance: -16.4% over one month.

Short interest was 1.8M shares at the Oct 30 settlement, down 5.4% from the prior report (3.4% of float, 5.0 days to cover).

Market cap$1.59B106.8M shares

Revenue · quarter——

Diluted EPS——

P/E · TTM—

Net margin—

Dividend yieldNone

Range since Sep 2513.23 – 20.64−27.7% from high

Volume994.9K2.56× 20-day avg

Volatility · 60d—Annualised

Short % of float3.4%5.0 days to cover

Net cash—

Next earnings—Not scheduled

Split-adjusted performance

1W +12.2%1M −16.4%3M —6M —YTD —1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 419 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size77

Industry medians: 6-month return −26.6%, revenue growth +10.0%, net margin −36.2%, P/E 17.1×.

Short interest

Details →

Shares short1.8M−5.4% vs prior

Days to cover5.0Settled Oct 30

% of float3.4%

Short vol. 10d65.0%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ADRXADARx Pharmaceuticals	$14.91	+12.11%	—	—	—	—	$1.59B
GENBGenerate Biomedicines	$12.57	−6.82%	—	—	−1065.2%	—	$1.61B	Compare
ANIPANI Pharmaceuticals	$71.06	−0.04%	−10.7%	+27.6%	11.3%	14.9	$1.62B	Compare
SLSSELLAS Life Sciences Group	$8.03	−4.63%	+8.2%	—	—	—	$1.62B	Compare
RAPPRapport Therapeutics	$25.85	−4.33%	−31.9%	—	—	—	$1.53B	Compare
RAREUltragenyx Pharmaceutical	$16.27	−2.57%	−36.9%	+8.1%	−68.2%	—	$1.66B	Compare
PGENPrecigen	$4.66	−1.27%	+1.3%	+2437.6%	48.2%	68.5	$1.67B	Compare
NRIXNurix Therapeutics	$15.60	−4.47%	−2.5%	+8426.3%	81.7%	5.8	$1.70B	Compare
STOKStoke Therapeutics	$26.20	−5.62%	−16.5%	+5.9%	−654.3%	—	$1.71B	Compare

News about ADARx Pharmaceuticals

All news →

No recent articles focused on ADARx Pharmaceuticals.

Quick answers

What does ADARx Pharmaceuticals do?: Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs.
What is ADRX's market cap?: $1.59B, based on the Nov 12 close of $14.91.
How much of ADRX is sold short?: 1.8M shares, 3.4% of float, as of Oct 30, 2026.
What sector is ADRX in?: Healthcare, in the Pharmaceuticals industry.

About ADARx Pharmaceuticals

Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.

HQ: San Diego, CAListed Sep 25, 2026adarx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology